US government

#ABPI #Alzheimer's #Clinical trial #Metabolomics #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #Peptides #UK government #US government

DDW Highlights: 9 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a trade agreement between the UK and the US promised to support… Read More

#Podcasts

#ABPI #Alzheimer's #Clinical trial #Metabolomics #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #Peptides #UK government #US government

This week in Drug Discovery (1 – 5 December) 

News round-up for 1 – 5 December by Bruno Quinney, Content Team at DDW.  This week in DDW, a trade agreement between the UK and the US promises to support the life sciences industry and secure access to drugs. Elsewhere, novel therapies could break new ground in treating neurodegenerative diseases.  The… Read More

#News

Protesting against health inequalities
#ABPI #NHS #UK government #US government

UK-US trade deal good news for UK life sciences, ABPI says 

The UK-US trade agreement is good news for NHS patients and will support the UK life sciences industry, the Association of the British Pharmaceutical Industry (ABPI) says.  The agreement will ensure that UK pharmaceutical exports to the US continue to face 0% tariffs for three years. In… Read More

#News

#FDA #US government

Trump praises infertility product awarded FDA ‘voucher’

US President Donald Trump has welcomed the US Food and Drug Administration (FDA) awarding a ‘voucher’ to infertility product Pergoveris as part of an unprecedented new scheme.  Pergoveris was one of nine recipients of FDA vouchers handed out under the new Commissioner’s National Priority Voucher (CNPV) pilot… Read More

#News

#Drug development #Investment #Life sciences #Treehill Partners #US government

Expert opinion on life sciences in a Trump/RFK era

Max Baumann, Co-Founder and Head of Execution of Treehill Partners, discusses what investors, drug developers, and the rest of the life science sector can do to prepare for the Trump/RFK era. The arrival of a new US administration generates significant industry-wide speculation and anticipation regarding new policies and agendas that may… Read More

#Business & Investment #Exclusive Content #Opinion